{"id":6892,"date":"2024-05-20T12:39:53","date_gmt":"2024-05-20T18:39:53","guid":{"rendered":"https:\/\/genteopa.com\/central\/?p=6892"},"modified":"2024-05-20T12:39:53","modified_gmt":"2024-05-20T18:39:53","slug":"la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente","status":"publish","type":"post","link":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/","title":{"rendered":"La FDA autoriza el implante de un chip cerebral de Neuralink en un segundo paciente"},"content":{"rendered":"\n<p>La empresa anunci\u00f3 un plan para evitar problemas como el ocurrido con el primer paciente <\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"502\" src=\"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\" alt=\"\" class=\"wp-image-6893\" style=\"width:840px;height:auto\" srcset=\"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg 800w, https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES-300x188.jpg 300w, https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES-768x482.jpg 768w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><figcaption class=\"wp-element-caption\">Reuters\/Dado Ruvic<\/figcaption><\/figure>\n\n\n\n<p>La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk, implantar un chip cerebral en una segunda persona despu\u00e9s de que la compa\u00f1\u00eda ofreci\u00f3 solucionar un problema que le ocurri\u00f3 al primer paciente, inform\u00f3 el lunes el Wall Street Journal.<\/p>\n\n\n\n<p>Reuters inform\u00f3 la semana pasada, citando a personas familiarizadas con el asunto, que el problema revelado por Neuralink, en el que peque\u00f1os cables dentro del cerebro de su primer paciente se hab\u00edan salido de su posici\u00f3n, es un problema que la empresa de Elon Musk conoce desde hace a\u00f1os.<\/p>\n\n\n\n<p>La empresa pretende solucionar el problema introduciendo algunos de los cables del dispositivo a mayor profundidad en el cerebro, seg\u00fan el informe del WSJ, que cit\u00f3 a una persona familiarizada con la empresa y un documento.<\/p>\n\n\n\n<p>Neuralink y la FDA no respondieron de inmediato a una solicitud de Reuters para hacer comentarios.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La empresa anunci\u00f3 un plan para evitar problemas como el ocurrido con el primer paciente La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk, implantar un chip cerebral en una segunda persona despu\u00e9s de que la compa\u00f1\u00eda ofreci\u00f3 solucionar un problema que le ocurri\u00f3 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[9],"tags":[62],"class_list":["post-6892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tecnologia","tag-tecnologia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La FDA autoriza nuevamente el implante de un chip cerebral<\/title>\n<meta name=\"description\" content=\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA autoriza nuevamente el implante de un chip cerebral\" \/>\n<meta property=\"og:description\" content=\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/\" \/>\n<meta property=\"og:site_name\" content=\"Central Noticias\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/centralnoticiascr\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-20T18:39:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"502\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"diana\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"diana\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/\"},\"author\":{\"name\":\"diana\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#\\\/schema\\\/person\\\/05fe4535b67c9703eebc4f00294cb711\"},\"headline\":\"La FDA autoriza el implante de un chip cerebral de Neuralink en un segundo paciente\",\"datePublished\":\"2024-05-20T18:39:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\",\"keywords\":[\"Tecnolog\u00eda\"],\"articleSection\":[\"Tecnolog\u00eda\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/\",\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/\",\"name\":\"La FDA autoriza nuevamente el implante de un chip cerebral\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\",\"datePublished\":\"2024-05-20T18:39:53+00:00\",\"description\":\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#primaryimage\",\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\",\"contentUrl\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg\",\"width\":800,\"height\":502,\"caption\":\"Un tel\u00e9fono inteligente con el logotipo de Neuralink en la placa base de un ordenador en esta ilustraci\u00f3n tomada el 15 de mayo de 2024. REUTERS\\\/Dado Ruvic\\\/\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/genteopa.com\\\/central\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA autoriza el implante de un chip cerebral de Neuralink en un segundo paciente\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#website\",\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/\",\"name\":\"Central Noticias\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/genteopa.com\\\/central\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#organization\",\"name\":\"Central Noticias\",\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/logo-central-color.png\",\"contentUrl\":\"https:\\\/\\\/genteopa.com\\\/central\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/logo-central-color.png\",\"width\":917,\"height\":957,\"caption\":\"Central Noticias\"},\"image\":{\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/centralnoticiascr\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@CentralNoticiasCR\",\"https:\\\/\\\/www.tiktok.com\\\/@centralnoticiascr\",\"https:\\\/\\\/www.instagram.com\\\/centralnoticiascr\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/genteopa.com\\\/central\\\/#\\\/schema\\\/person\\\/05fe4535b67c9703eebc4f00294cb711\",\"name\":\"diana\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g\",\"caption\":\"diana\"},\"sameAs\":[\"https:\\\/\\\/genteopa.com\\\/central\"],\"url\":\"https:\\\/\\\/genteopa.com\\\/central\\\/autor\\\/diana\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA autoriza nuevamente el implante de un chip cerebral","description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/","og_locale":"es_ES","og_type":"article","og_title":"La FDA autoriza nuevamente el implante de un chip cerebral","og_description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk","og_url":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/","og_site_name":"Central Noticias","article_publisher":"https:\/\/www.facebook.com\/centralnoticiascr\/","article_published_time":"2024-05-20T18:39:53+00:00","og_image":[{"width":800,"height":502,"url":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","type":"image\/jpeg"}],"author":"diana","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"diana","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#article","isPartOf":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/"},"author":{"name":"diana","@id":"https:\/\/genteopa.com\/central\/#\/schema\/person\/05fe4535b67c9703eebc4f00294cb711"},"headline":"La FDA autoriza el implante de un chip cerebral de Neuralink en un segundo paciente","datePublished":"2024-05-20T18:39:53+00:00","mainEntityOfPage":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/genteopa.com\/central\/#organization"},"image":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#primaryimage"},"thumbnailUrl":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","keywords":["Tecnolog\u00eda"],"articleSection":["Tecnolog\u00eda"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/","url":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/","name":"La FDA autoriza nuevamente el implante de un chip cerebral","isPartOf":{"@id":"https:\/\/genteopa.com\/central\/#website"},"primaryImageOfPage":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#primaryimage"},"image":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#primaryimage"},"thumbnailUrl":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","datePublished":"2024-05-20T18:39:53+00:00","description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA) ha permitido a Neuralink, la empresa del multimillonario Elon Musk","breadcrumb":{"@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#primaryimage","url":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","contentUrl":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","width":800,"height":502,"caption":"Un tel\u00e9fono inteligente con el logotipo de Neuralink en la placa base de un ordenador en esta ilustraci\u00f3n tomada el 15 de mayo de 2024. REUTERS\/Dado Ruvic\/"},{"@type":"BreadcrumbList","@id":"https:\/\/genteopa.com\/central\/la-fda-autoriza-el-implante-de-un-chip-cerebral-de-neuralink-en-un-segundo-paciente\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/genteopa.com\/central\/"},{"@type":"ListItem","position":2,"name":"La FDA autoriza el implante de un chip cerebral de Neuralink en un segundo paciente"}]},{"@type":"WebSite","@id":"https:\/\/genteopa.com\/central\/#website","url":"https:\/\/genteopa.com\/central\/","name":"Central Noticias","description":"","publisher":{"@id":"https:\/\/genteopa.com\/central\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genteopa.com\/central\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/genteopa.com\/central\/#organization","name":"Central Noticias","url":"https:\/\/genteopa.com\/central\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/genteopa.com\/central\/#\/schema\/logo\/image\/","url":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2025\/10\/logo-central-color.png","contentUrl":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2025\/10\/logo-central-color.png","width":917,"height":957,"caption":"Central Noticias"},"image":{"@id":"https:\/\/genteopa.com\/central\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/centralnoticiascr\/","https:\/\/www.youtube.com\/@CentralNoticiasCR","https:\/\/www.tiktok.com\/@centralnoticiascr","https:\/\/www.instagram.com\/centralnoticiascr\/"]},{"@type":"Person","@id":"https:\/\/genteopa.com\/central\/#\/schema\/person\/05fe4535b67c9703eebc4f00294cb711","name":"diana","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a14a8c45faee5f6c7e1911c1dc4eff386e7c33920e23770a2be70b095a5ec543?s=96&d=mm&r=g","caption":"diana"},"sameAs":["https:\/\/genteopa.com\/central"],"url":"https:\/\/genteopa.com\/central\/autor\/diana\/"}]}},"jetpack_featured_media_url":"https:\/\/genteopa.com\/central\/wp-content\/uploads\/2024\/05\/2024-05-20T125956Z_1_LYNXMPEK4J0G8_RTROPTP_4_NEURALINK-MUSK-WIRES.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/posts\/6892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/comments?post=6892"}],"version-history":[{"count":0,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/posts\/6892\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/media\/6893"}],"wp:attachment":[{"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/media?parent=6892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/categories?post=6892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genteopa.com\/central\/wp-json\/wp\/v2\/tags?post=6892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}